

JUL 17 2012

**510(k) SUMMARY**

Date Prepared: July 2, 2012

**A. Sponsor**

Navilyst Medical, Inc  
26 Forest Street  
Marlborough, MA 01752

**B. Contact**

Wanda Carpinella  
Director, Global Regulatory Affairs  
508-650-7929

Lorraine M. Hanley  
Vice President, Global Regulatory Affairs  
508-608-7945

**C. Device Name**

Trade Name:	NMI MC
Common/Usual name:	Microcatheter
Classification Name:	Diagnostic Intravascular Catheter
	21 CFR §870.1200, ProCode DQO
Classification	Class II

**D. Predicate Device(s)**

The NMI MC described in this submission is identical in terms of intended use, materials, design, components and technological characteristics to the predicate NMI MC cleared under K112124 and K111368. The change involves a labeling change only.

**E. Device Description**

The NMI MCs has an outside diameter of 2.8F and 2.4F and has a nominal inside diameter of 0.027" and 0.021", respectively, along the entire catheter length. The MC has a braided reinforced shaft, which transitions from a stiffer proximal region to a flexible 30cm distal end. A radiopaque marker is located 1mm from the distal end of the catheter to identify the location of the distal tip under fluoroscopic visualization. The MC has a hydrophilic coating applied to the outer surface of the distal end. The proximal end of the MC contains a Luer fitting and strain relief. The device is provided sterile and intended for single procedure use.

**F. Intended Use**

The NMI MC is intended for use in small vessels and supraselective anatomy during diagnostic and interventional procedures in the peripheral vasculature. Upon access of the desired region, the microcatheter can be used for the controlled and selective infusion of diagnostic, therapeutic and embolic materials. All products delivered through the microcatheter must be used in accordance with the original manufacturer's instruction for use. The catheter is not intended for use in coronary or neuro-vasculature.

**G. Technology Characteristics**

The proposed device is identical in terms of materials, design, and technological characteristics as the currently marketed NMI MC.

**H. Performance Data**

The results of infusate compatibility testing support the labeling change described in this submission and demonstrate substantial equivalence of the proposed device.

**I. Conclusion**

The submission is for a labeling change only. No design, dimensional or material changes have been made to the predicate device. The results of the non-clinical testing support the labeling change described in this submission demonstrate substantial equivalence of the proposed device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room -WO66-G609  
Silver Spring, MD 20993-0002

JUL 17 2012

Navylist Medical, Inc.  
c/o Ms. Wanda Carpinella  
26 Forest St.  
Marlborough, MA 01752

Re: K121954

Trade/Device Name: Embarc Microcatheter  
Regulation Number: 21 CFR 870.1200  
Regulation Name: Diagnostic intravascular catheter  
Regulatory Class: Class II (two)  
Product Code: DQO  
Dated: July 2, 2012  
Received: July 3, 2012

Dear Ms. Carpinella:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



*for* Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

### Indications for Use

510(k) Number (if known): K121954

Device Name: NMI Microcatheter

Indication For Use:

The NMI Microcatheter is intended for use in small vessels and superselective anatomy during diagnostic and interventional procedures in the peripheral vasculature. Upon access of the desired region, the microcatheter can be used for the controlled and selective infusion of diagnostic, therapeutic and embolic materials. All products must be used in accordance with the original manufacturer's instructions for use. The catheter is not intended for use in coronary or neuro- vasculature.

Prescription Use   X    
(21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use       
(21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*M J Hillman*  
(Division Sign-Off)  
Division of Cardiovascular Devices

510(k) Number K121954